Treatment of cardiomyocytes with an inhibitor of GSK3-β causes cell proliferation [78], while genetic ablation of GSK3-β in mice leads to cardiomyocyte hyperproliferation followed by hypertrophic cardiomyopathy [79]. Here, GSK3B is linked to hypertrophic cardiomyopathy.